Literature DB >> 31602418

Variability in expression of the human MDR1 drug efflux transporter and genetic variation of the ABCB1 gene: implications for drug-resistant epilepsy.

Anna Heinrich1, Xiao-Bo Zhong2, Theodore P Rasmussen2.   

Abstract

Among individuals diagnosed with epilepsy, as many as one in three develop resistance to antiepileptic drugs (AEDs) thus rendering their seizures refractory to treatment. Despite current antiepileptic drugs (AEDs) having a variety of modes of action, seizures in drug-resistant individuals often persist even after treatment with two or more drugs. The underlying cause of this broad resistance is currently under debate, but two dominant theories have emerged and have been widely studied. Here we discuss current literature investigating the "transporter theory", the idea that individuals present with drug resistance due to genetic variability in the ABCB1 gene encoding the efflux transporter multidrug resistance protein 1 (MDR1). Results of in vitro and in vivo studies suggest that variability in the expression of the MDR1 transporter may be closely tied to drug resistance. While there is much support for this hypothesis from molecular and mechanistic studies, population-based studies of ABCB1 polymorphisms are divergent in their conclusions, and there is need for additional investigations.

Entities:  

Keywords:  ATP binding cassette membrane protein 1 gene (ABCB1); P-glycoprotein (P-gp); antiepileptic drugs (AEDs); drug resistant epilepsy; epilepsy; multidrug resistance protein 1 (MDR1)

Year:  2018        PMID: 31602418      PMCID: PMC6785833          DOI: 10.1016/j.cotox.2018.12.004

Source DB:  PubMed          Journal:  Curr Opin Toxicol        ISSN: 2468-2020


  65 in total

1.  A long-term follow-up of zonisamide monotherapy.

Authors:  Katsuyuki Fukushima; Masakazu Seino
Journal:  Epilepsia       Date:  2006-11       Impact factor: 5.864

2.  Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences.

Authors:  Anna Biró; Ulrich Stephani; Tiziana Tarallo; Thomas Bast; Kurt Schlachter; Martin Fleger; Gerhard Kurlemann; Barbara Fiedler; Steffen Leiz; Marina Nikanorova; Markus Wolff; Arnd Müller; Christina Selch; Martin Staudt; Gerhard Kluger
Journal:  Neuropediatrics       Date:  2015-03-02       Impact factor: 1.947

3.  Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy.

Authors:  G Barcs; E B Walker; C E Elger; A Scaramelli; H Stefan; Y Sturm; A Moore; G Flesch; L Kramer; J D'Souza
Journal:  Epilepsia       Date:  2000-12       Impact factor: 5.864

4.  Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs.

Authors:  Luca Cucullo; Mohammed Hossain; Ed Rapp; Toby Manders; Nicola Marchi; Damir Janigro
Journal:  Epilepsia       Date:  2007-02-22       Impact factor: 5.864

5.  Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier.

Authors:  Björn Bauer; Anika M S Hartz; Gert Fricker; David S Miller
Journal:  Mol Pharmacol       Date:  2004-09       Impact factor: 4.436

6.  Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy.

Authors:  Dong Wook Kim; Manho Kim; Sang Kun Lee; Rami Kang; Seo-Young Lee
Journal:  Seizure       Date:  2006-03-20       Impact factor: 3.184

7.  Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities.

Authors:  B Huber; W Bömmel; I Hauser; V Horstmann; S Liem; Th May; T Meinert; E Robertson; L Schulz; M Seidel; M Tomka-Hoffmeister; W Wagner
Journal:  Seizure       Date:  2004-04       Impact factor: 3.184

8.  Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice.

Authors:  Jun-Sheng Wang; Ying Ruan; Robin M Taylor; Jennifer L Donovan; John S Markowitz; C Lindsay DeVane
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

9.  Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals.

Authors:  Jun-Sheng Wang; Robin Taylor; Ying Ruan; Jennifer L Donovan; John S Markowitz; C Lindsay De Vane
Journal:  Neuropsychopharmacology       Date:  2004-03       Impact factor: 7.853

10.  Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese.

Authors:  Patrick Kwan; Larry Baum; Virginia Wong; Ping Wing Ng; Colin Ht Lui; Ngai Chuen Sin; Andrew C F Hui; Evelyn Yu; Lawrence K S Wong
Journal:  Epilepsy Behav       Date:  2007-05-22       Impact factor: 2.937

View more
  1 in total

Review 1.  Pharmacogenetics of Drug-Resistant Epilepsy (Review of Literature).

Authors:  Beata Smolarz; Marianna Makowska; Hanna Romanowicz
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.